在低氧引起的肺高血压中控制内皮功能障碍的ErbB3
Jin-Song Bian1,2, Jingyu Chen3, Junting Zhang1
1Key Laboratory of Shenzhen Respiratory Disease, Shenzhen Institute of Respiratory Disease, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology; the Second Clinical Medical College, Jinan University), China (J.-S.B., J.Z., Y.L., R.C., X.N.).
在肺高血压 (PH) 中,ErbB3 升高调节,导致疾病的进展. 用MM-121向ErbB3显示了PH治疗的治疗潜力.
科学领域:
- 心血管研究
- 细胞生物学
- 分子医学
背景情况:
- 肺高血压 (PH) 涉及血管重塑和肺动脉内皮细胞功能障碍.
- 人体表皮生长因子受体3 (ErbB3) 是受体氨酸激酶,参与细胞过程.
- 目前的PH疗法缺乏治愈方案,强调需要新的治疗点.
研究的目的:
- 研究ErbB3在肺高血压中的病理作用.
- 评估ErbB3作为PH的潜在生物标志物和治疗点.
主要方法:
- 使用微阵列,免疫光和西方抹黑来分析ErbB3表达.
- 使用动物PH模型对ErbB3进行基因操纵 (过度表达,删除,淘汰).
- 研究了人体细胞中YB-1和低氧诱导因素的下游机制.
主要成果:
- 在PH患者的血清,肺和肺动脉内皮细胞中,ErbB3显著上升.
- 在小鼠中,ErbB3过度表达加剧了PH表型,而ErbB3删除/抑制则改善了它们.
- 确定了一个新的ErbB3-YB-1-HIF1α信号通路和一个ErbB3-periostin-HIF1α正反循环.
- 在低氧诱导的PH模型中,抗ErbB3抗体MM-121表现出预防性和治疗性作用.
结论:
- ErbB3 是肺高血压发病的一个关键媒介.
- ErbB3 是一种新且有前途的PH治疗点.
- MM-121显示出治疗PH的显著潜力.
相关概念视频
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal


